

Sociodemographic and Clinicopathological Features of Lymphoma Patients in Indonesia: A report from Special Region of Yogyakarta Province

Nungki Anggorowati	Department of Anatomical Pathology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Special Region of Yogyakarta, Indonesia. Anatomical Pathology Laboratory Unit, Integrated Clinical Laboratory, Universitas
Indrawati ,	Anatomical Pathology Laboratory Unit, Integrated Clinical Laboratory, Universitas Gadjah Mada Academic Hospital,
Amira L Dhyanti	Special Region of Yogyakarta, Indonesia Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Special Region of Yogyakarta, Indonesia.
Hafidh Arkananda	Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Special Region of Yogyakarta,
Salsabilla Hasna Rizki	Indonesia. Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Special Region of Yogyakarta, Indonesia.
Syahru Agung Setiawan	Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Gadjah
Miraz Radhea Bagaskoro	Mada, Special Region of Yogyakarta, Indonesia. Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Special Region of Yogyakarta, Indonesia.
Mardiah Suci Hardianti	Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Special Region of Yogyakarta, Indonesia.

Introduction: Lymphoma as a heterogeneous disease has various characteristics not only in the clinical manifestation but also in sociodemographic aspect. Epidemiological data with sociodemographic description in lymphoma is still unexplored.

Objective: This study aimed to provide updated and detailed description of lymphoma with emphasis on patient characteristics, sociodemographic data and hematologic findings.

Materials and Methods: This was an observational descriptive study with a cross-sectional design. The data were from the medical records in Dr. Sardjito Hospital, a national referral hospital in the Special Region of Yogyakarta Province Indonesia from 2012 to 2018. All lymphoma patients > 18 years were included. Patients' characteristics, socio-demographic indicators, tumor characteristic and hematological finding were recorded. The difference of socio-demographic, clinical and laboratory characteristics between Non Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) was analyzed with Chi-Square, Fisher-Exact, and Mann-Whitney test (P <0.05 was statistically significant).

Results: There were 675 cases. Male predominated, mean age at diagnosis was 54.1 for NHL and 42.3 for HL. There was significant difference in the mean of age (p=0.000), occupation



(P=0.035) and educational level (P=0.020) between NHL and HL patients. B cell NHL was found to be the most common type of lymphoma, with DLBCL being the most common histopathological type. Hematological findings were found to be within the normal range. **Conclusion:** There are significant difference in the mean of age, occupation and education level between NHL and HL patients. Further study to explain the scientific reasons of the difference are required.

Introduction

Lymphoma is a malignant disease of mature lymphocyte in lymphoid tissue generally divided into Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) [1, 2]. The etiology of lymphoma is still poorly understood, immune system deficiency, infectious agents, exposure to certain organic chemicals (herbicides and pesticides), infection of Epstein-Barr Virus (EBV), immunodeficiency and pharmaceuticals are assumed to contribute to an increased risk of its occurrence [3]. Characteristics of lymphoma may diverse in each patient, but the most of the patients show enlarged lymph nodes, B symptoms (fever, unexplained weight loss, and night sweats), abdominal pain, and enlarged liver or spleen [4, 5].

Malignant lymphoma contributes 3.37% of all cancers worldwide. It is more common in developed countries than in developing countries. East Asia region has the lowest incidence rates [3]. NHL as the most common type of lymphoma occurred worldwide is the fifth most common malignancy in adult. B-Cell type accounts for 90% of all lymphoma cases, and Diffuse Large B-Cell Lymphoma (DLBCL) is the most frequent subtype among NHL [6]. T-cell NHL comprises of approximately 10-15% of the case [7]. NHLs occurs slightly more in male than in female [8]. Hodgkin Lymphoma cases comprised only about 1% of all malignancies [4]. It is one of the most common lymphoid malignancies occurring in young adults. Hodgkin's lymphoma exposes bimodal distribution with a first peak in the third decade and a second peak after the age of fifty and men are slightly predominant [9]. In Indonesia, NHL is on the seventh rank of cancers, while HL is on the twenty ninth. In 2018, new cases number of NHL was more than 14.000 cases, while HL accounted for more than 1,000 cases (WHO, 2018). The research conducted by Indonesian Ministry of Health in 2013 showed that the prevalence of lymphoma in Indonesia was 0.06% with the Special Region of Yogyakarta Province contributing to highest prevalence of 0.25% with estimation of about 890 patients and West Java constituted the highest estimation of patients at about 2,728 [10]. Frequent characteristics of lymphoma patients in Sanglah hospital, province of Bali from the data of year 2014, showed male gender (76%), age group of 61 to 76 years old, presence of enlarged lymph nodes (100%), anemia incidence (72%), and DLBCL as the most common lymphoma (68%) [11]. Epidemiological study with sociodemographic description in lymphoma is still rare. Therefore, this study is aimed to provide a detail and updated description about lymphoma including patient characteristics, sociodemographic data and basic hematological data.

Materials and Methods

Study Population

This study was an observational descriptive study with a cross-sectional design. The data was procured from the medical records in Dr. Sardjito Hospital Yogyakarta, a national referral hospital in the Special Region of Yogyakarta Province from the year of 2012-2018. All patients with confirmed diagnosis of lymphoma with the age at diagnosis of older than 18 years old were included. Exclusion criteria were unreadable or missing data, or inconclusive pathology result. Date of birth, sex, ECOG performance status, and nutritional status were withdrawn and indicated as patients' characteristics. Socio-demographic indicators were education, occupation, and address. Occupational status was coded and categorized as follows: unemployed and retired were included in not working population; teacher/lecturer/civil servants in non-medical field, doctor/

nurse/paramedic/healthcare worker, private employee, and student were included in non-manual workers; Indonesian national army/police, farmer/fisherman, laborer were classified into manual workers; entrepreneur/businessman; and others.

We also examined tumor characteristic which consisted of nodal and extranodal site predilection, treatment, histopathological types, and Ann Arbor staging. Hematological finding included hemoglobin level (Hb), leukocyte (neutrophils, lymphocytes, eosinophils, basophils, and monocytes) count, thrombocyte count, LDH levels and ECOG performance status.

Statistical analysis

Descriptive statistics were used to describe the distribution of patients' characteristic, sociodemographic, tumor status, and hematological finding. Categorical data was presented by frequencies and percentages, while numerical data was presented by means, medians, and standard deviations. The difference of socio-demographic, clinical and laboratory characteristics between NHL and HL was analyzed using Chi-Square, Fisher-Exact, and Mann-Whitney test, with P value <0.05 considered to be statistically significant. All data analysis was done using Statistical Package for Social Sciences (SPSS) version 25. Ethical clearance of this study was issued by the Ethical committee of Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada.

Results

There were 675 lymphoma patients during the year of 2012-2018. However, not all of the patients had complete data. Therefore, analysis was done based on the data available. Based on the result analysis, it was evident that lymphoma was more common among males (n=384). The mean age at diagnosis was 54.1 years old for NHL and 42.3 years old for HL. Patients mostly came with ECOG performance stage score of 1 (n=402). The nutritional status of the patients was generally normal (n=379) (Table 1).

Variable (N total)	NHLn (%)	HLn (%)	P value	
Sex (675)			0.586	
Male (384)	359 (93.5)	25 (6.5)		
Female (291)	275 (94.5)	16 (5.5)		
Age, mean±SD	54.1±13.6	42.3±14.0	0	
Performance Stage (525)			0.966	
0 (52)	48 (92.3)	4 (3.2)		
1 (402)	378 (94)	24 (6)		
2 (63)	59 (93.7)	4 (6.3)		
3 (4)	4 (100)	0 (0)		
4 (1)	1 (100)	0 (0)		
Nutritional Status (649)			0.226	
Underweight (177)	169 (95.5)	8 (4.5)		
Normal (379)	356 (93.9)	23 (6.1)		
Overweight (83)	78 (94)	5 (6)		
Obese (18)	15 (83.3)	3 (16.7)		

 Table 1. Characteristics of Lymphoma Patients at Dr. Sardjito Hospital in the Period of 2012-2018.

Patients' occupation were mostly farmer or fisherman (n=101) followed by entrepreneur or businessman (n=87). Based on their educational level, most patients had finished elementary school (n=169) followed by senior high school (n=132). Most patients who seek treatment at Dr. Sardjito Hospital were actually from outside the province of Yogyakarta Special Region-which



consisted of 4 districts and 1 municipality (n=388) (Table 2).

Variable (N total)	NHL	HL	P value
Occupation (545)	n (%)	n (%)	
Unemployed1 (97)			0.035
Teacher/Lecturer/civil servants non-medical field2 (58)	92 (94.8)	5 (5.2)	
Doctor/Nurse/Paramedic/Heal thcare worker2 (4)	53 (91.4)	5 (8.6)	
Entrepreneur/Businessman (87)	4 (100)	0 (0)	
Indonesian National Army/Police3 (4)	83 (95.4)	4 (4.6)	
Private Employee2 (50)	3 (100)	0 (0)	
Student2 (11)	47 (94)	3 (6)	
Farmer/Fisherman3 (101)	8 (72.7)	3 (27.3)	
Laborer3 (73)	97 (96)	4 (4)	
Retired1 (54)	73 (100)	0 (0)	
Others (6)	54 (100)	0 (0)	
Education (422)	5 (83.3)	1 (16.7)	
No Formal Education (3)			0.02
Elementary (169)	3 (100)	0 (0)	
Junior High (58)	164 (97)	5 (3)	
Senior High (132)	58 (100)	0 (0)	
Diploma (20)	122 (92.4)	10 (5.9)	
Undergraduate (34)	19 (95)	1 (5)	
Post-graduate (6)	33 (97.1)	1 (2.9)	
Address (675)	4 (66.7)	2 (33.3)	
Yogyakarta Special Region Province (287)			0.564
Sleman district (104)	96 (92.3)	8 (7.7)	
Yogyakarta municipality (32)	29 (90.6)	3 (9.4)	
Bantul district (68)	65 (95.6)	3 (4.4)	
Gunung Kidul dictrict (41)	38 (92.7)	3 (7.3)	
Kulon Progo district (42)	38 (90.5)	4 (9.5)	
Outside the Province (388)	368 (94.8)	20 (5.2)	

Table 2. Socio-demographic Characteristics of Lymphoma Patients at Dr. Sardjito Hospital in the Period of2012-2018.

1Not working; 2Non-manual workers; 3Manual worker

Differences in patient characteristics by lymphoma classification of NHL and HL were also provided in Table 1. There was a statistically significant difference between the means of age among NHL and HL population (P = < 0.000).

Our study also revealed a correlation between socio- demographic characteristics with NHL or HL patients. As shown in Table 2, there were significant differences among different occupation groups and in terms of education level in regard to classification of lymphoma (P=0.035 and P=0.020, respectively).

This study found that NHL B-Cell was the most prevalent lymphoma type. It accounted for 61.9% or 418 cases. Moreover, there were 201 cases of DLBCL observed (29.8%) which made DLBCL as the

most frequent subtype of lymphoma. It was followed by Classical Hodgkin Lymphoma, Nodular Sclerosing subtype (18 cases, 2.7%) and Follicular Lymphoma (16 cases, 2.4%) (Table 3).

Lymphoma Classification (675)Image: Classification (675)NHL B-Cell418 (61.9)NHL T-cell58 (8.6)Hodgkin's Lymphoma41 (6.1)NHL NOS158 (23.4)Lymphoma Subtypes (675)Image: Classification (Classification (Classif	Variable (N total)	N (%)
NHL B-Cell418 (61.9)NHL rcell58 (8.6)Hodgkin's Lymphoma41 (6.1)NHL NOS158 (23.4)Lymphoma Subtypes (675)1NHL B-Cell0DLBCL201 (29.8)NHL B-Cell, NOS160 (23.7)Follicular Lymphoma16 (2.4)T-Cell/Histiccyte-rich Large15 (2.2)B-Cell Lymphoma5 (0.7)Small Lymphocytic Lymphoma5 (0.7)Lymphoma MALT-type4 (0.6)Primary Mediastinal B-Cell Lymphoma3 (0.4)Extranodal Marginal Zone1 (0.1)B-Cell Lymphoma1 (0.1)NHL T-cell11 (1.6)Shape Cell Lymphoma1 (0.1)NHL T-cell Lymphoma2 (0.3)Anaplastic Large Cell Lymphoma7 (1.0)Cutaneous T-Cell Lymphoma2 (0.3)Anaplastic Large Cell Lymphoma1 (0.1)HCClassical Hodgkin Lymphoma, NoSGlassical Hodgkin Lymphoma, NoS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte-redominant Hodgkin Lymphoma1 (0.1)		
NHL T-cell58 (8.6)Hodgkin's Lymphoma41 (6.1)NHL NOS158 (23.4)Lymphoma Subtypes (675)158 (23.4)NHL B-Cell201 (29.8)DLECL201 (29.8)NHL B-Cell Jumphoma16 (2.4,)T-Cell/Histiocyte-rich Large15 (2.2)B-Cell Lymphoma16 (2.4)T-Cell/Histiocyte-rich Large15 (0.7)Bymphoma5 (0.7)Lymphoma5 (0.7)Lymphoma1 (0.1)B-cell Lymphoma1 (0.1)Extraoseous Plasmacytoma1 (0.1)NHL T-Cell1 (0.1)NHL T-Cell1 (0.1)NHL T-Cell Lymphoma37 (5.5)Extraoseous Plasmacytoma1 (1.6)Yup1Anaplastic Large Cell Lymphoma2 (0.3)Angoiamunoblastic T-Cell Lymphoma1 (0.1)HL1Classical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma1 (0.1)Ndat Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma1 (0.1)Nodal Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)		418 (61.9)
Hodgkin's Lymphoma41 (6.1)NHL NOS158 (23.4)Lymphoma Subtypes (675)NHL B-CellDLBCL201 (29.8)NHL B-Cell, NOS160 (23.7)Follicular Lymphoma16 (2.4)T-Cell/Histicoyte-rich Large15 (2.2)B-Cell Lymphoma12 (1.8)Burkitt Lymphoma5 (0.7)Lymphoma3 (0.4)Extraoseous Plasmacytoma1 (0.1)B-Cell Lymphoma3 (0.4)Extraoseous Plasmacytoma1 (0.1)NHL T-CellNHL T-CellNHL T-Cell Lymphoma, nasal1 (1.6)Ypp2 (0.3)Anglastic Large Cell Lymphoma2 (0.3)Anglostic T-Cell Lymphoma1 (0.1)HLClassical Hodgkin Lymphoma, NoS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich1 (0.1)Mixed CellularityClassical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich1 (0.1)Nodular Lymphora, Lymphocyte-rich1 (0.1)Nodular Lymphora, Lymphocyte-rich1 (0.1)		
NHL NOS158 (23.4)Lymphoma Subtypes (675)	Hodgkin's Lymphoma	
NHL B-Cell 201 (29.8) DLBCL 201 (29.8) NHL B-Cell, NOS 160 (23.7) Follicular Lymphoma 16 (2.4) T-Cell/Histiccyte-rich Large 15 (2.2) B-Cell Lymphoma 12 (1.8) Burkit Lymphorma 5 (0.7) Lymphoma MALT-type 4 (0.6) Primary Mediastinal B-Cell Lymphoma 3 (0.4) Extranodal Marginal Zone 1 (0.1) B-cell Lymphoma 2 (0.3) NHL T-cell 7 (1.0) NHL T-cell Lymphoma 2 (0.3) Anaplastic Large Cell Lymphoma 1 (0.1) HL Classical Hodgkin Lymphoma, NoS 9 (1.3) Classical Hodgkin Lymphoma, NOS 9 (1.3) 3 Classical Hodgkin Lymphoma, NOS 9 (1.3) 3 Classical Hodgkin Lymphoma, Lymphocyte-rich 3 (0.4) 3 Classical Hodgkin Lymphoma, NOS 9 (1.3) 3 Classical Hodgkin Lymphoma, NOS 9 (1.3) 3		
NHL B-Cell 201 (29.8) DLBCL 201 (29.8) NHL B-Cell, NOS 160 (23.7) Follicular Lymphoma 16 (2.4) T-Cell/Histiccyte-rich Large 15 (2.2) B-Cell Lymphoma 12 (1.8) Burkit Lymphorma 5 (0.7) Lymphoma MALT-type 4 (0.6) Primary Mediastinal B-Cell Lymphoma 3 (0.4) Extranodal Marginal Zone 1 (0.1) B-cell Lymphoma 2 (0.3) NHL T-cell 7 (1.0) NHL T-cell Lymphoma 2 (0.3) Anaplastic Large Cell Lymphoma 1 (0.1) HL Classical Hodgkin Lymphoma, NoS 9 (1.3) Classical Hodgkin Lymphoma, NOS 9 (1.3) 3 Classical Hodgkin Lymphoma, NOS 9 (1.3) 3 Classical Hodgkin Lymphoma, Lymphocyte-rich 3 (0.4) 3 Classical Hodgkin Lymphoma, NOS 9 (1.3) 3 Classical Hodgkin Lymphoma, NOS 9 (1.3) 3	Lymphoma Subtypes (675)	
NHL B-Cell, NOS160 (23.7)Follicular Lymphoma16 (2.4)T-Cell/Histicozte-rich Large15 (2.2)B-Cell Lymphoma12 (1.8)Burkitt Lymphoma5 (0.7)Lymphoma MALT-type4 (0.6)Primary Mediastinal B-Cell Lymphoma3 (0.4)Extranodal Marginal Zone1 (0.1)B-cell Lymphoma10.1)B-cell Lymphoma1 (0.1)Btrtaroodal Marginal Zone1 (0.1)B-tranodal Marginal Zone1 (0.1)Secent Lymphoma2Extranoseous Plasmacytoma1 (0.1)NHL T-Cell11 (1.6)NHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)type2Anaplastic Large Cell Lymphoma2 (0.3)Angloimmunoblastic T-Cell Lymphoma1 (0.1)HL10.1)HC10.1)Classical Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)	NHL B-Cell	
Follicular Lymphoma16 (2.4)T-Cell/Histiocyte-rich Large15 (2.2)B-Cell Lymphoma12 (1.8)Small Lymphocytic Lymphoma5 (0.7)Lymphoma MALT-type4 (0.6)Primary Mediastinal B-Cell Lymphoma3 (0.4)Extranodal Marginal Zone1 (0.1)B-cell LymphomaExtraosseous PlasmacytomaNHL T-Cell10.1)NHL T-Cell NOS37 (5.5)Extranodal NK/T-cell lymphoma, nasal11 (1.6)type1Anaplastic Large Cell Lymphoma2 (0.3)Anaplastic T-Cell Lymphoma1 (0.1)HL10.1)Classical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma1 (0.1)Ndular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)	DLBCL	201 (29.8)
T-Cell/Histocyte-rich Large15 (2.2)B-Cell Lymphoma12 (1.8)Small Lymphocytic Lymphoma5 (0.7)Burkitt Lymphoma5 (0.7)Lymphoma MALT-type4 (0.6)Primary Mediastinal B-Cell Lymphoma3 (0.4)Extranodal Marginal Zone1 (0.1)B-cell Lymphoma1 (0.1)B-cell Lymphoma1Extraosseous Plasmacytoma1 (0.1)NHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)type1Anaplastic Large Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HLClassical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma1 (0.1)Ndular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)	NHL B-Cell, NOS	160 (23.7)
B-Cell LymphomaISmall Lymphocytic Lymphoma12 (1.8)Burkitt Lymphoma5 (0.7)Lymphoma MALT-type4 (0.6)Primary Mediastinal B-Cell Lymphoma3 (0.4)Extranodal Marginal Zone1 (0.1)B-cell Lymphoma1 (0.1)B-cell Lymphoma1 (0.1)NHL T-Cell1 (0.1)NHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)type1Anaplastic Large Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HL1Classical Hodgkin Lymphoma, NoS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma2 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma1 (0.1)Nixed Cellularity1 (0.1)Nixed Cellularity1 (0.1)Nixed Cellularity1 (0.1)Nodular Lymphora1 (0.1)Nodular Lymphora1 (0.1)	Follicular Lymphoma	16 (2.4)
Small Lymphocytic Lymphoma12 (1.8)Burkitt Lymphoma5 (0.7)Lymphoma MALT-type4 (0.6)Primary Mediastinal B-Cell Lymphoma3 (0.4)Extranodal Marginal Zone1 (0.1)B-cell Lymphoma1Extraosseous Plasmacytoma1 (0.1)NHL T-Cell1NHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)type1Anaplastic Large Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HL1Classical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma1 (0.1)Mixed Cellularity1Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphoryte Predominant Hodgkin Lymphoma1 (0.1)	T-Cell/Histiocyte-rich Large	15 (2.2)
Burkitt Lymphoma5 (0.7)Lymphoma MALT-type4 (0.6)Primary Mediastinal B-Cell Lymphoma3 (0.4)Extranodal Marginal Zone1 (0.1)B-cell Lymphoma1 (0.1)B-cell Lymphoma1 (0.1)NHL T-Cell1 (0.1)NHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)type1Anaplastic Large Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HL1Classical Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nixed Cellularity1 (0.1)Nixed Cellularity1 (0.1)Nixed Cellularity1 (0.1)Nixed Cellularity1 (0.1)Nixed Cellularity1 (0.1)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)	B-Cell Lymphoma	
Lymphoma MALT-type4 (0.6)Primary Mediastinal B-Cell Lymphoma3 (0.4)Extranodal Marginal Zone1 (0.1)B-cell Lymphoma1Extraosseous Plasmacytoma1 (0.1)NHL T-CellNHL T-CellNHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)typeAnaplastic Large Cell Lymphoma7 (1.0)Cutaneous T-Cell Lymphoma1 (0.1)HLClassical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nixed Cellularity1 (0.1)Nodular Lymphoma1 (0.1)	Small Lymphocytic Lymphoma	12 (1.8)
Primary Mediastina B-Cell Lymphoma3 (0.4)Extranodal Marginal Zone1 (0.1)B-cell Lymphoma1 (0.1)B-cell Lymphoma1 (0.1)NHL T-Cell1 (0.1)NHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)type1Anaplastic Large Cell Lymphoma2 (0.3)Cutaneous T-Cell Lymphoma1 (0.1)HL1Classical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)	Burkitt Lymphoma	5 (0.7)
Extranodal Marginal Zone1 (0.1)B-cell Lymphoma1Extraosseous Plasmacytoma1 (0.1)NHL T-Cell1NHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)type1Anaplastic Large Cell Lymphoma7 (1.0)Cutaneous T-Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HL1Classical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)	Lymphoma MALT-type	4 (0.6)
B-cell LymphomaIExtraosseous Plasmacytoma1 (0.1)NHL T-CellINHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)typeIAnaplastic Large Cell Lymphoma7 (1.0)Cutaneous T-Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HLIClassical Hodgkin Lymphoma, NoS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)	Primary Mediastinal B-Cell Lymphoma	3 (0.4)
Extraosseous Plasmacytoma1 (0.1)NHL T-Cell37 (5.5)NHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)type7 (1.0)Anaplastic Large Cell Lymphoma7 (1.0)Cutaneous T-Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HLClassical Hodgkin Lymphoma, Nodular SclerosingHodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)	Extranodal Marginal Zone	1 (0.1)
NHL T-CellImage: style="text-align: center;">Image: style="text-align: center;">Image: style="text-align: center;">Image: style="text-align: style="text-align: center;">Image: style="text-align: st	B-cell Lymphoma	
NHL T cell, NOS37 (5.5)Extranodal NK-/T-cell lymphoma, nasal11 (1.6)type-Anaplastic Large Cell Lymphoma7 (1.0)Cutaneous T-Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HL-Classical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)	Extraosseous Plasmacytoma	1 (0.1)
Extranodal NK-/T-cell lymphoma, nasal11 (1.6)typeAnaplastic Large Cell Lymphoma7 (1.0)Cutaneous T-Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HLClassical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)	NHL T-Cell	
typeAnaplastic Large Cell Lymphoma7 (1.0)Cutaneous T-Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HLIClassical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma,7 (1.0)Mixed CellularityIClassical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphoma1 (0.1)	NHL T cell, NOS	37 (5.5)
Anaplastic Large Cell Lymphoma7 (1.0)Cutaneous T-Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HLClassical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma,7 (1.0)Mixed Cellularity3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphora1 (0.1)	Extranodal NK-/T-cell lymphoma, nasal	11 (1.6)
Cutaneous T-Cell Lymphoma2 (0.3)Angioimmunoblastic T-Cell Lymphoma1 (0.1)HLClassical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma,7 (1.0)Mixed CellularityClassical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma, Lymphocyte-depleted1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)		
Angioimmunoblastic T-Cell Lymphoma1 (0.1)HL	Anaplastic Large Cell Lymphoma	7 (1.0)
HLImage: Classical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma,7 (1.0)Mixed Cellularity7Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)		
Classical Hodgkin Lymphoma, Nodular Sclerosing18 (2.7)Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma,7 (1.0)Mixed Cellularity3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)		1 (0.1)
Hodgkin Lymphoma, NOS9 (1.3)Classical Hodgkin Lymphoma,7 (1.0)Mixed Cellularity7Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)		
Classical Hodgkin Lymphoma,7 (1.0)Mixed Cellularity7Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)		
Mixed CellularityImage: Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)		9 (1.3)
Classical Hodgkin Lymphoma, Lymphocyte-rich3 (0.4)Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)		7 (1.0)
Classical Hodgkin Lymphoma, Lymphocyte-depleted2 (0.3)Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)		
Classical Hodgkin Lymphoma1 (0.1)Nodular Lymphocyte Predominant Hodgkin Lymphoma1 (0.1)		
Nodular Lymphocyte Predominant Hodgkin Lymphoma 1 (0.1)		
NHL, NOS 158 (23.4)		
	NHL, NOS	158 (23.4)

 Table 3. Lymphoma Histopathology Type.

Based on nodal involvement, this study found that most of the patient (37.8%) had single nodal. The three most common sites of nodal predilection were in cervical (43%), followed by Waldeyer's ring (13.8%) and axillary (11.5%). For the extranodal involvement, 42.2% of the patients showed to have single extranodal with the 3 most frequent sites of predilection were head and neck (14.2%), nose and paranasal sinuses (12.8%), and spleen in HL cases (3.5%). There were 45.1% patients with Ann Arbor stage I disease (Table 4).

Variable (N total)	N (%)
Single/ Multiple Nodal (474)	
No Tumor	211 (30.8)



Multiple215 (31.4)Single/Multiple Extranodal (357)300 (45.7)Single277 (42.2)Multiple80 (12.2)Nodal Predilection (474)2Axillary79 (11.5)Cervical296 (43.0)Inguinal & Femoral122 (17.7)Intra-abdominal21 (3.1)Intra-abdominal20 (2.9)Mediastinal20 (2.9)Mesenteric26 (3.8)Paraaortic61 (8.9)Pelvic25 (3.6)Retroperitoneal3 (0.4)Suplean (HL)8 (1.2)Suplean (HL)17 (2.5)Head and neck98 (14.2)Intesthum37 (5.4)Retroperitoneal36 (5.2)Liver15 (2.2)Mammary12 (1.7)Nose and paranasi sinues88 (12.8)Pulmo22 (3.2)Spleen (NHL)24 (3.5)Thorax10 (1.5)Ann Arbor Stage (517)1I10 (1.5 (3.5)Hu70 (15 (3.5)Hu70 (15 (3.5) <th>Single</th> <th>259 (37.8)</th>	Single	259 (37.8)
No Tumor 300 (45.7) Single 277 (42.2) Multiple 80 (12.2) Multiple 80 (12.2) Axillary 79 (11.5) Cervical 296 (43.0) Inguinal & Femoral 122 (17.7) Intra-abdominal 21 (3.1) Intra-abdominal 21 (3.1) Intra-abdominal 20 (2.9) Mediastinal 20 (2.9) Mesenteric 26 (3.8) Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Supen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) Extranodal Predilection (357) Bone 23 (3.3) CNS 2 (0.3) Gaster 2 (0.3) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 96 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) <td< td=""><td>Multiple</td><td>215 (31.4)</td></td<>	Multiple	215 (31.4)
Single 277 (42.2) Multiple 80 (12.2) Nodal Predilection (474) Axillary 79 (11.5) Cervical 296 (43.0) Inguinal & Femoral 122 (17.7) Intra-abdominal 21 (3.1) Intra-abdominal 21 (3.1) Intra-bdominal 20 (2.9) Mediastinal 20 (2.9) Mesenteric 26 (3.8) Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) Extranodal Predilection (357) Bone 23 (3.3) CNS 20 (2.9) Gaster 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 36 (5.2) Mammary 12 (1.7)	Single/Multiple Extranodal (357)	
Multiple 80 (12.2) Nodal Predilection (474)	No Tumor	300 (45.7)
Nodal Predilection (474) Axillary 79 (11.5) Cervical 296 (43.0) Inguinal & Femoral 122 (17.7) Intra-abdominal 21 (3.1) Intra-abdominal 21 (3.1) Intra-abdominal 20 (2.9) Mediastinal 20 (2.9) Mesenteric 26 (3.8) Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Supraclavicular 17 (2.5) Waldgeyr's ring 95 (13.8) Extranodal Predilection (357) E Bone 23 (3.3) CNS 2 (0.3) Musculcoutaneous 20 (2.9) Gester 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) S	Single	277 (42.2)
Axillary 79 (11.5) Cervical 296 (43.0) Inguinal & Femoral 122 (17.7) Intra-abdominal 21 (3.1) Intra-bodominal 21 (3.1) Intra-bodominal 20 (2.9) Mediastinal 20 (2.9) Mesenteric 26 (3.8) Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Spleen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) Extranodal Predilection (357) Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax </td <td>Multiple</td> <td>80 (12.2)</td>	Multiple	80 (12.2)
Cervical 296 (43.0) Inguinal & Femoral 122 (17.7) Intra-abdominal 21 (3.1) Intra-thoracic 3 (0.4) Mediastinal 20 (2.9) Mesenteric 26 (3.8) Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) Bone Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 1 I	Nodal Predilection (474)	
Inguinal & Femoral 122 (17.7) Intra-abdominal 21 (3.1) Intra-bdominal 21 (3.1) Intra-bdominal 20 (2.9) Mediastinal 20 (2.9) Mesenteric 26 (3.8) Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Sylpeen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) Bone Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann ar	Axillary	79 (11.5)
Intra-abdominal 21 (3.1) Intrathoracic 3 (0.4) Mediastinal 20 (2.9) Mesenteric 26 (3.8) Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Spleen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) E Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) I I 233 (45.1) I 154 (29.8)	Cervical	296 (43.0)
Intrathoracic 3 (0.4) Mediastinal 20 (2.9) Mesenteric 26 (3.8) Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Spleen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) B Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 11 I 154 (29.8)	Inguinal & Femoral	122 (17.7)
Mediastinal 20 (2.9) Mesenteric 26 (3.8) Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Spleen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) Bone Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) I I 233 (45.1) II 154 (29.8)	Intra-abdominal	21 (3.1)
Mesenteric 26 (3.8) Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Spleen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) E Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 1 I 233 (45.1) II 154 (29.8)	Intrathoracic	3 (0.4)
Paraaortic 61 (8.9) Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Spleen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) B Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 1 I 233 (45.1) II 154 (29.8)	Mediastinal	20 (2.9)
Pelvic 25 (3.6) Retroperitoneal 3 (0.4) Spleen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) 10 Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 1 I 233 (45.1) II 154 (29.8)	Mesenteric	26 (3.8)
Retroperitoneal 3 (0.4) Spleen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) Bone Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 1 I 233 (45.1) II 154 (29.8)	Paraaortic	61 (8.9)
Spleen (HL) 8 (1.2) Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357)	Pelvic	25 (3.6)
Supraclavicular 17 (2.5) Waldeyer's ring 95 (13.8) Extranodal Predilection (357) Extranodal Predilection (357) Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 1 I 233 (45.1) II 154 (29.8)	Retroperitoneal	3 (0.4)
Waldeyer's ring 95 (13.8) Extranodal Predilection (357) Image: Construction of the system o	Spleen (HL)	8 (1.2)
Extranodal Predilection (357) 23 (3.3) Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 11 I 233 (45.1) II 154 (29.8)	Supraclavicular	17 (2.5)
Bone 23 (3.3) CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 1 I 233 (45.1) II 154 (29.8)	Waldeyer's ring	95 (13.8)
CNS 2 (0.3) Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 11 II 154 (29.8)	Extranodal Predilection (357)	
Musculocutaneous 20 (2.9) Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) II 154 (29.8)	Bone	23 (3.3)
Gaster 2 (0.3) Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) II 154 (29.8)	CNS	2 (0.3)
Genital 17 (2.5) Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) II 154 (29.8)	Musculocutaneous	20 (2.9)
Head and neck 98 (14.2) Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) II 154 (29.8)	Gaster	2 (0.3)
Intestinum 37 (5.4) Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) II 154 (29.8)	Genital	17 (2.5)
Retroperitoneal 36 (5.2) Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) II 154 (29.8)	Head and neck	98 (14.2)
Liver 15 (2.2) Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) II 15 (2.2)	Intestinum	37 (5.4)
Mammary 12 (1.7) Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) II 154 (29.8)	Retroperitoneal	36 (5.2)
Nose and paranasal sinuses 88 (12.8) Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) II 154 (29.8)	Liver	15 (2.2)
Pulmo 22 (3.2) Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) I 154 (29.8)	Mammary	12 (1.7)
Spleen (NHL) 24 (3.5) Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) I 154 (29.8)	Nose and paranasal sinuses	88 (12.8)
Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) I 154 (29.8)	Pulmo	22 (3.2)
Thorax 10 (1.5) Ann Arbor Stage (517) 233 (45.1) I 154 (29.8)	Spleen (NHL)	24 (3.5)
I 233 (45.1) II 154 (29.8)	Thorax	10 (1.5)
II 154 (29.8)	Ann Arbor Stage (517)	
	I	233 (45.1)
TH 79 (15 3)	II	154 (29.8)
¹¹¹ ⁷ (13.3)	III	79 (15.3)
IV 51 (9.9)	IV	51 (9.9)

Table 4. Tumor Characteristics.

The hematologic characteristic of the patients was found to be within the normal range (Table 5).

Variable	Mean	SD
Hemoglobin	12.3 mg/dL	1.9
Platelet count	329.2 cells/µL	263.7
WBC count	10.1 × 103 cells/ μL	13.2
Differential WBC countSegmented Neutrophils	8.5 × 103 cells/ μL	43.5
Band Neutrophils	0.8 × 103 cells/ μL	2.5
Lymphocytes	3.2×103 cells/ µL	14



Original Research

Monocytes	1.0 × 103 cells/ µL	4.2
Eosinophils	0.3 × 103 cells/ μL	0.4
Basophils	0.1 × 103 cells/ μL	0.5

Table 5. Hematologic Findings.

Discussion

Our study found that lymphoma patients in Dr. Sardjito hospital was mostly male (n=384). This male predominance could also be found in numerous studies, including a study in 2020 conducted in Chinese population [12] and a multicenter study of NHL in developing country in 2016 [13]. Regarding age, there was a significant difference in the mean of age between NHL and HL population (p=<0.000). This study found the mean of age for NHL and HL were 54.1 ± 13.6 years and 42.3 ± 14.0 years respectively. In other study conducted in Sudan in 2020 found that the mean age of HL was 47.14 ± 22.31 years and NHL was 40.22 ± 24.62 years [14].

The nutritional status of the patients was mostly normal (n=379). The nutritional status of overweight and obese are associated to a worse prognosis and lower quality of life in lymphoma patients. There is further dysregulation in iron metabolism in overweight and obesity patient which could lead to the presence of anemia. Furthermore, pro-inflammatory cytokines – such as IL-6 and IL-1 – are also increased due to presence of excess adipose tissue, worsening the systemic inflammation caused by the malignancy itself [15]. Hence, the normal and underweight status of the patients is considered a protective factor.

The most prevalent occupation was found to be farmer/fisherman (n=101). There had been evidence that exposure to chemicals used as herbicides and pesticides – namely organochlorine, organophosphate, and phenoxyl acid compounds – are considered to increase the risk of developing lymphoma [16]. There were significant differences among different occupation and the lymphoma classification (p=0.035). It is supported by a study conducted in Iran in 2012 to 150 lymphoma cases admitted to two reference university hospitals in Tehran that they found a significant difference between patients' occupation and lymphoma classification in Tehran. Some occupations may cause increase in NHL risks such as farming, textile industry, metal working, veterinaries, rubber industry, and benzene exposure [17].

Regarding the education level, there was statistically significant difference between HL and NHL (p= 0.020). This finding went against the findings of a European multicenter study that was conducted in 2010 which stated no consistent association between education and the overall risk of HL or NHL [18]. However, the same study also stated that there was positive correlation between educational level and risk of B cell chronic lymphocytic leukemia (B-CLL) in women. The risk of DLBCL was found to be significantly lower in patient with university degree compared to those of lower educational level.

This study found that 61.9% of all patients were diagnosed with B-Cell NHL and 29.8% were DLBCL. This is similar to a study from Sanglah Hospital, Province of Bali in Indonesia in 2015 [19]. Based on the Ann Arbor Stage, about 45.1% of all patients in this study had stage I. This is in contrary with two studies that stated that the largest number of proportions with Ann Arbor stage was stage IV [17, 18]. Regarding to nodal site involvement, we found the majority of the cases were with single site (37.8%) and the most affected location was cervical region (43%). This finding is similar with a study conducted in French where the majority were single tumor (42.2%) with cervical lymph nodes (36.8%) as the most common site [20]. Our study also found extranodal involvement in 54.4% patients, mostly with single involvement with most predilection of head and neck area (14.2%) followed by nose and paranasal sinuses area (12.8%). Other study conducted in the province of Jakarta-Indonesia also stated the same finding where 50 cases (100%) showed to have \leq 1 extranodal involvement and neck as the most common area (86 cases, 54.1%) [21].

The basic hematological finding of hemoglobin, white blood cell count, and platelet count were found to be within the normal range with the respective mean of 12.3 mg/dl, 10.1×103 cells/ µL, and 329.2 cells/µL. Similar result was reported from Sanglah Hospital Bali [19]. Aberrations in blood examination typically occur when there was bone marrow involvement. Therefore, it could be concluded that most patient did not come with bone marrow involvement. Our data showed that patient who initially diagnosed with bone extranodal tumor was only 3.3%.

There are several limitations of this study. The retrospective design of the study only permitted us to work with the existing data with no possibility of tracing the patients to complete the unavailable data. The study was also done in a single center which may not be able to reflect the real condition of the population.

In conclusion, We retrieved 675 data from Dr. Sardjito Hospital in Yogyakarta Special Region Province Indonesia from the year of 2012-2018. We found out that lymphoma was more frequent in male patients, with the mean age of 54.1 years old in NHL and 42.3 years old in HL. DLBCL was found to be the most common histopathological type of lymphoma. Sociodemographic analysis revealed the statistically significant difference in the occupation and education level of NHL and HL patients. The difference in mean age of NHL and HL patients was also found to be statistically significant. Further study should be done to analyze in order to further explain the scientific reasons behind significance of occupation and education to the risk of lymphoma.

Acknowledgements

This study was funded by Hibah Dana Masyarakat (DAMAS) Research, Faculty of Medicine, Public Health and Nursing, Universitas Gajdah Mada. Authors declared no conflict of interest.

References

References

- Nair Reena, Kakroo Abhishek, Bapna Ajay, Gogia Ajay, Vora Amish, Pathak Anand, Korula Anu, Chakrapani Anupam, Doval Dinesh, Prakash Gaurav, Biswas Ghanashyam, Menon Hari, Bhattacharya Maitreyee, Chandy Mammen, Parihar Mayur, Vamshi Krishna M., Arora Neeraj, Gadhyalpatil Nikhil, Malhotra Pankaj, Narayanan Prasad, Nair Rekha, Basu Rimpa, Shah Sandip, Bhave Saurabh, Bondarde Shailesh, Bhartiya Shilpa, Nityanand Soniya, Gujral Sumeet, Tilak T. V. S., Radhakrishnan Vivek. Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group. *Indian Journal of Hematology & Blood Transfusion: An Official Journal of Indian Society of Hematology and Blood Transfusion*. 2018; 34(3)DOI
- 2. Caron A A, Jacobson, Longo DL. Harrison's Principles of Internal Medicine. 20th ed. Chapter 104: Non-Hodgkin's Lymphoma. McGraw Hill; 2018.
- 3. Huh Jooryung. Epidemiologic overview of malignant lymphoma. *The Korean Journal of Hematology.* 2012; 47(2)DOI
- 4. Gobbi PG, Ferreri AJM, Ponzoni M, Levis A. Hodgkin lymphoma. *Crit Rev Oncol Hematol.* 2013; 85(2):216-237.
- 5. Martin P. Understanding Non-Hodgkin Lymphoma (Lymphoid Neoplasms) [Internet]. Lymphoma.org. 2020 [cited 17 November 2020]. *Available from: https://lymphoma.org/wp.*
- 6. Najafi Safa, Payandeh Mehrdad, Sadeghi Masoud. Clinicopathology Figures and Survival of Non-Hodgkin's Lymphoma in Iran. *Iranian Journal of Cancer Prevention*. 2017; 10(1)DOI
- 7. Phan Anh, Veldman Rachel, Lechowicz Mary Jo. T-cell Lymphoma Epidemiology: the Known

and Unknown. Current Hematologic Malignancy Reports. 2016; 11(6)DOI

- Bray Freddie, Ferlay Jacques, Soerjomataram Isabelle, Siegel Rebecca L., Torre Lindsey A., Jemal Ahmedin. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*. 2018; 68(6)DOI
- 9. Mozaheb Z. Epidemiology of hodgkin's lymphoma. *Health (N Y).* 2013; 05(05):17-2.
- Kementerian Kesehatan RI. Data dan Kondisi Penyakit Limfoma di Indonesia [Internet]. Pusat Data dan Informasi Kementerian Kesehatan RI. 2015 [cited 17 November 2020]. Available from:

https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/infodatin-limfoma.pdf..

- 11. Suryadiarsa IPDP, Rena NMRA, Dharmayuda TG. Tingkat Harapan Hidup Pasien Limfoma Non-Hodgkin Berdasarkan Skor Ipi Yang Mendapatkan Kemoterapi Lini Pertama Di Rsup Sanglah Denpasar Tahun 2014. E-J Med Udayana [Internet]. 2019 May 14 [cited 2020 Nov 3];8(5). Available from: https://ojs.unud.ac.id/index.php/eum/article/view/51656.
- 12. Liu Weiping, Ji Xinqiang, Song Yuqin, Wang Xiaopei, Zheng Wen, Lin Ningjing, Tu Meifeng, Xie Yan, Ping Lingyan, Ying Zhitao, Zhang Chen, Deng Lijuan, Wu Meng, Feng Feier, Leng Xin, Sun Yingli, Du Tingting, Zhu Jun. Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. *Cancer Medicine*. 2020; 9(11)DOI
- Perry Anamarija M., Diebold Jacques, Nathwani Bharat N., MacLennan Kenneth A., Müller-Hermelink Hans K., Bast Martin, Boilesen Eugene, Armitage James O., Weisenburger Dennis D.. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. *Haematologica*. 2016; 101(10)DOI
- 14. Abdalhabib Ezeldine K.. Relative Frequencies and Patterns of Malignant Lymphoma in a Reference Centre in Khartoum, Sudan: A Descriptive Study Based on the WHO Classification of Lymphoid Neoplasms. *Asian Pacific Journal of Cancer Care*. 2020; 5(2)DOI
- 15. Aigner Elmar, Feldman Alexandra, Datz Christian. Obesity as an emerging risk factor for iron deficiency. *Nutrients.* 2014; 6(9)<u>DOI</u>
- 16. Bassey EE. Non-Hodgkin's Lymphoma [Internet]. Interventions in Pediatric Dentistry: Open Access Journal. 2018 [cited 2020 Mar 15]. Available from: https://lupinepublishers.com/index.php.
- Aminian O, Abedi A, Chavoshi F, Ghasemi M, Rahmati-Najarkolaei F. Evaluation of Occupational Risk Factors in Non-Hodgkin Lymphoma and Hodgkin's Disease in Iranian Men. Iran J Cancer Prev. 2012; 5(4):189-193.
- 18. Hermann S, Rohrmann S, Linseisen J, Nieters A, Khan A, Gallo V, et al. Level of education and the risk of lymphoma in the European prospective investigation into cancer and nutrition. *J Cancer Res Clin Oncol.* 2010; 136(1):71-77.
- 19. Paramartha IKA, Rena RA. Karakteristik Pasien Limfoma Maligna Di Rsup Sanglah Tahun 2015. *6*. 2017;9.
- 20. Laurent Camille, Do Catherine, Gourraud Pierre-Antoine, Paiva Geisilene Russano, Valmary Séverine, Brousset Pierre. Prevalence of Common Non-Hodgkin Lymphomas and Subtypes of Hodgkin Lymphoma by Nodal Site of Involvement: A Systematic Retrospective Review of 938 Cases. *Medicine*. 2015; 94(25)DOI
- 21. Reksodiputro Ary. Multicentre Epidemiology and Survival Study of B Cell Non Hodgkin Lymphoma Patients In Indonesia. *Journal of Blood Disorders & Transfusion*. 2015; 06<u>DOI</u>